ArticleFrontiers in aging neuroscience2025
Early detection of mild cognitive impairment utilizing ocular biomarker-based risk scoring nomogram.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of cognitive impairment is increasing along with global aging. Early retinal structural and vascular changes, prior to the onset of clinically detectable retinal pathologies, have been increasingly associated with cognitive changes. However, the evidence related to the predictive performance of these biomarkers remains limited. Therefore, this study aimed to develop and validate a nomogram-based scoring tool for opportunistic screening of mild cognitive impairment (MCI). Methods: This study prospectively recruited participants aged 60 years or older, including those with normal cognitive function. The retinal images were scanned using optical coherence tomography and angiography. Following the selection of potential predictors, a logistic regression model was built to predict MCI. Subsequently, a dynamic nomogram was developed to facilitate risk scoring in a clinical setting. The model's discriminative ability was evaluated using the area under the receiver operating characteristic curve, along with diagnostic metrics of sensitivity and specificity at 95% confidence interval (CI). The model was internally validated using bootstrapping. Decision curve analysis was conducted to evaluate the model's clinical impact and utility. Results: The model indicated that central macular thickness ( Conclusion: This study developed and internally validated a dynamic, nomogram-based scoring tool for early detection of MCI that integrates non-invasive retinal and visual biomarkers. The model demonstrated high discriminative power and substantial clinical net benefit. Further evaluation of the model's prognostic value in predicting further cognitive decline may support its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.